Insmed, Inc.

Day range

$92.96 – $94.34

Open

$93.44

Prev close

$93.39

Volume

3.37M

Market cap

$20.39B

Shares out

218.38M

P/E

—

P/S

17.93

P/B

26.92

P/FCF

—

ROE

-115.5%

ROA

-41.6%

Debt/Equity

0.75

Div yield

0.00%

As of Oct 23, 2026

• Director appointmentOct 20, 2026

  On October 16, 2026, the Board of Directors (the "Board") of Insmed Incorporated (the "Company") appointed Paul Hudson and Utpal Koppikar as members of the Board, effective October 19, 2026. Mr. Hudson serves as a Class II director, and Mr. Koppikar serves as a Class I director, with each subject to election at the Company's 2027 Annual Meeting of Shareholders. Mr. Hudson has been appointed to serve on the Board's Compensation Committee, and Mr. Koppikar has been appointed to serve on the Board's Audit Committee.

• Cfo departureOct 5, 2026

  On October 5, 2026, Insmed Incorporated (the "Company") announced that Sara Bonstein, the Company's Chief Financial Officer, would be separating from the Company, effective October 30, 2026, and the Company has a search underway to identify a successor. The separation is not related to any disagreement between Ms. Bonstein and the Company on any matter relating to the Company's accounting practices, financial statements, internal controls or operations.

• Investor presentationJul 16, 2026

  The Company will host a conference call to discuss the 12-month data of the OLE Study on July 16, 2026, at 8:00 a.m., Eastern Time, and a live webcast of the call will be available through the investor relations section of the Company's website. A copy of the slide presentation to be used by the Company during the conference call is attached hereto as Exhibit 99.2.

• Annual meeting resultsMay 15, 2026

  The annual meeting of shareholders of Insmed Incorporated (the "Company") was held on May 13, 2026 (the "Annual Meeting"). Set forth below are the voting results for each of the proposals submitted to a vote of the Company's shareholders at the Annual Meeting: Proposal 1.Election of Two Class II Directors. By the following votes, shareholders elected Elizabeth McKee Anderson and Clarissa Desjardins, Ph.D., to serve as Class II directors until the Company's 2029 Annual Meeting of Shareholders.

• Clinical trial resultsApr 7, 2026

  On April 7, 2026, the Company issued a press release announcing topline efficacy and safety results from its Phase 2b CEDAR study of brensocatib in patients with HS. At Week 16, study participants experienced a 45.5% and 40.3% reduction from baseline in AN count in the brensocatib 10 mg and 40 mg arms, respectively, compared to a 57.1% reduction in the placebo arm.

Days to cover

6.5

Short interest

13.8M

Avg volume

2.12M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
  negativeZacks Investment Research· Oct 22, 2026
• INSM Stock Slides on CFO Exit, Reiterates '26 Sales View
  negativeZacks Investment Research· Oct 6, 2026
• Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback
  negativeZacks Investment Research· Oct 1, 2026
• FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce
  positiveZacks Investment Research· Sep 22, 2026
• LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?
  negativeZacks Investment Research· Sep 11, 2026